SecBot SecBot
SECBOTREPLAY Home › Report › RDY

RDY · Dr

DR REDDYS LABORATORIES LTD · 6-K filed Aug 17, 2026 at 06:57 ET

At the news

MIXEDIMPACT 5/10

6-K filed Aug 17, 2026 at 06:57 ET

Dr. Reddy's filed two 6-Ks on August 14, 2026, disclosing USFDA inspection outcomes at two different facilities. The first filing reports that a GMP inspection at its Mirfield, UK API facility has been classified as 'Voluntary Action Indicated (VAI)' and officially closed, a positive resolution. The second filing reports that a GMP inspection at its Bachupally, Hyderabad formulations facility (FTO-3) resulted in a Form 483 with four observations, which the company will address. The net read is mixed: one facility receives a clean regulatory close-out, while another faces new compliance scrutiny.

  • USFDA classified the inspection outcome at the Mirfield, UK API facility as 'Voluntary Action Indicated (VAI)' and officially closed the inspection under 21 CFR 20.64(d)(3).
  • USFDA completed a GMP inspection at the Bachupally, Hyderabad formulations facility (FTO-3) from August 6 to August 14, 2026, and issued a Form 483 with four observations.
  • The company stated it will address the four observations from the Form 483 within the stipulated timeline.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access